Focused On-demand Library for tRNA (uracil-5-)-methyltransferase homolog A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

mRNA (uracil-5-)-methyltransferase TRMT2A

Alternative UPACC:

Q8IZ69; D3DX25; Q32P57; Q96ME6; Q9H732


tRNA (uracil-5-)-methyltransferase homolog A, also known as mRNA (uracil-5-)-methyltransferase TRMT2A, plays a crucial role in post-transcriptional modification. It is a S-adenosyl-L-methionine-dependent methyltransferase, responsible for the formation of 5-methyl-uridine in tRNAs and some mRNAs. This enzyme specifically targets uridine at position 54 (m5U54) in cytosolic tRNAs, enhancing their stability and function, and also modifies some mRNAs.

Therapeutic significance:

Understanding the role of tRNA (uracil-5-)-methyltransferase homolog A could open doors to potential therapeutic strategies. Its pivotal function in RNA stability and protein synthesis regulation highlights its potential as a target for drug discovery, aiming to modulate gene expression in various diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.